World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
84
Citations
32991
World Ranking
1341
National Ranking
690

James L. Riley publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where James L. Riley sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 191 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

James L. Riley D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where James L. Riley sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 84 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

James L. Riley is affiliated with the University of Pennsylvania in the United States, focusing extensively on research within the fields of Medicine and Immunology and Microbiology. Their work spans several subfields including Immunology, Oncology, Molecular Biology, Genetics, and Virology.

The scientist's main research topics cover a range of areas, including:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • HIV Research and Treatment
  • T-cell and B-cell Immunology
  • Virus-based gene therapy research
  • Immunotherapy and Immune Responses
  • Viral Infectious Diseases and Gene Expression in Insects

James L. Riley has published frequently in several prominent venues. The most common publication outlets include:

  • The Journal of Immunology
  • Nature Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood
  • Molecular Therapy

Recent papers authored by or involving Riley demonstrate a focus on CAR T cell technologies and HIV-related immunotherapies. Notable publications include:

  • PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial, 2022, Nature Medicine
  • Genetic engineering of T cells for immunotherapy, 2021, Nature Reviews Genetics
  • Recommendations for measuring HIV reservoir size in cure-directed clinical trials, 2020, Nature Medicine
  • Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo, 2020, Nature Medicine
  • CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication, 2021, Journal of Clinical Investigation

Throughout their career, Riley has collaborated repeatedly with several researchers, forming frequent coauthoring partnerships with:

  • Carl H. June
  • Gavin I. Ellis
  • Colby R. Maldini
  • Julie K. Jadlowsky
  • Pablo Tebas

Best Publications

  • CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

    Richard V. Parry;Jens M. Chemnitz;Kenneth A. Frauwirth;Anthony R. Lanfranco

  • The CD28 signaling pathway regulates glucose metabolism.

    Kenneth A Frauwirth;James L Riley;Marian H Harris;Richard V Parry

  • Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

    Michael C. Milone;Jonathan D. Fish;Jonathan D. Fish;Carmine Carpenito;Richard G. Carroll

  • Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

    Elena E. Perez;Jianbin Wang;Jeffrey C. Miller;Yann Jouvenot;Yann Jouvenot

  • SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.

    Jens M. Chemnitz;Richard V. Parry;Kim E. Nichols;Carl H. June

  • Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

    Carmine Carpenito;Michael C. Milone;Raffit Hassan;Jacqueline C. Simonet

  • Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation

    Edward Y. Woo;Heidi Yeh;Christina S. Chu;Katia Schlienger

  • PD-1 signaling in primary T cells.

    James L. Riley

  • Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

    John Scholler;Troy L. Brady;Gwendolyn Binder-Scholl;Wei-Ting Hwang

  • Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

    Brian J. Cameron;Andrew B. Gerry;Joseph Dukes;Jane V. Harper

  • Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

    Marcela V. Maus;Anna K. Thomas;Debra G.B. Leonard;David Allman

  • PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

    Unknown

  • Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T Cells Expressing a Mesothelin - Specific Chimeric Antibody Receptor

    Edmund K. Moon;Carmine Carpenito;Jing Sun;Liang-Chuan S. Wang

  • Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning

    James L. Riley;Carl H. June;Bruce R. Blazar

  • The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.

    Shoba Amarnath;Courtney W. Mangus;Courtney W. Mangus;James C. M. Wang;Fang Wei

  • Role of PD-1 during effector CD8 T cell differentiation.

    Eunseon Ahn;Koichi Araki;Masao Hashimoto;Weiyan Li

  • FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression

    Bin Li;Arabinda Samanta;Xiaomin Song;Kathryn T. Iacono

  • Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

    Benjamin Alan Youngblood;Kenneth J. Oestreich;Kenneth J. Oestreich;Sang-Jun Ha;Sang-Jun Ha;Jaikumar Duraiswamy

  • DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.

    Graham Simmons;Jacqueline D. Reeves;Case C. Grogan;Luk H. Vandenberghe

  • Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors

    Edmund K. Moon;Liang-Chuan Wang;Douglas V. Dolfi;Caleph B. Wilson

  • The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

    James L. Riley;Carl H. June

  • CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.

    Jens M. Chemnitz;James L. Riley;Kenneth A. Frauwirth;Inbal Braunstein

Frequent Co-Authors

Carl H. June
Carl H. June University of Pennsylvania
Bruce L. Levine
Bruce L. Levine University of Pennsylvania
Richard G. Carroll
Richard G. Carroll University of Pennsylvania
Bruce R. Blazar
Bruce R. Blazar University of Minnesota
Michael C. Milone
Michael C. Milone University of Pennsylvania
Michael C. Holmes
Michael C. Holmes Ambys Medicines
Marcela V. Maus
Marcela V. Maus Harvard University
John E. Wagner
John E. Wagner University of Minnesota
Jeffrey S. Miller
Jeffrey S. Miller University of Minnesota
Philip D. Gregory
Philip D. Gregory Sangamo BioSciences (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA can open doors to various healthcare and research-related careers. For those interested in nursing-related paths, numerous educational options allow for flexibility and advancement. For example, exploring the online nursing programs for non nurses can be an excellent way to enter the nursing field without prior experience, providing foundational knowledge and practical skills.

Advanced nursing professionals may consider specialized tracks such as becoming an Acute Care Nurse Practitioner. Programs focused on acute care nurse practitioner programs offer targeted training for those looking to handle complex patient cases in hospital settings.

Additionally, accelerated options exist for those who want to fast-track their nursing careers. The accelerated NP programs are designed to help students earn their nurse practitioner credentials efficiently while balancing other commitments.

Understanding potential salary outcomes is also crucial when planning a career. Resources such as the dnp salary by state page give a comprehensive overview of earnings, helping graduates make informed decisions based on geographic and economic factors.

Best Scientists Citing James L. Riley

Trending Scientists

Recently Published Articles